Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Research Library

Survodutide research

7 articles to explore, with links to 9 original sources.

About Survodutide

Survodutide is a peptide analogue used in research on glucagon and GLP-1 receptor signaling.

Understand the science

Explore study findings

  • What the survodutide cardiovascular trial was designed to count

    Survodutide is an investigational peptide that activates the glucagon and GLP-1 receptors. The SYNCHRONIZE cardiovascular study was designed to examine whether cardiovascular events occurred at different rates in adults with excess body weight assigned to survodutide or placebo.

    2 sources (2023, 2026)

  • Why the two LIVERAGE studies use different liver outcomes

    Survodutide is an investigational peptide that acts on the glucagon and GLP-1 receptors. The LIVERAGE registry records describe two trials that ask different questions about liver disease at different stages of scarring.

    3 sources (2024, 2026)

  • What the Chinese and Japanese trials tell us about who was studied

    Survodutide is an investigational peptide that acts at glucagon and GLP-1 receptors. Two 2026 design reports described how researchers set up randomized weight-management trials in China and Japan, including who could enroll and when outcomes would be measured.

    2 sources (2026)

  • What an MRI showed about liver fat in SYNCHRONIZE-MASLD

    Survodutide is an investigational glucagon and GLP-1 receptor agonist peptide. A phase 3 study reported in 2026 asked whether it changed liver fat and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, or MASLD.

    2 sources (2024, 2026)

  • Why the earlier MASH trial examined liver tissue directly

    Survodutide is an investigational peptide with activity at the glucagon and GLP-1 receptors. The older direct study for the biopsy question was a phase 2 trial in adults with confirmed metabolic dysfunction-associated steatohepatitis, or MASH, and varying degrees of scarring.

    2 sources (2024, 2026)

Check methods and identity

  • How SYNCHRONIZE-2 measured weight in adults with type 2 diabetes

    Survodutide is an investigational peptide that activates the glucagon receptor and the GLP-1 receptor. The phase 3 SYNCHRONIZE-2 trial asked what happened to body weight in adults with type 2 diabetes and excess body weight who were assigned to survodutide or placebo.

    2 sources (2026)

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice.